Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT03514784
PHASE1/PHASE2

Combination Probiotic: BB-12 With LGG (Different Doses) in Treating Children With Autism Spectrum Disorder

Sponsor: The University of Texas Health Science Center, Houston

View on ClinicalTrials.gov

Summary

This protocol is a blinded randomized controlled study of the effects of BB-12 with LGG at different doses in 70 healthy children with autism spectrum disorders at lower and higher doses over an 56-day period and a 28- day observation period. The study is being conducted in order to assess safety and tolerability of the probiotic (BB-12 with LGG) at 2 different doses of BB-12 with LGG. Identifying effects on behaviors in healthy children with ASD using SRS-2 and ABC, GI symptoms using GI symptom severity index, and relevant biomarkers of inflammation, microbiota, and metabolites. Primary testing and procedures will be conducted at the University of Texas Health Science Center at Houston and Memorial Hermann. Biomarker identification includes Integrative analysis of plasma metabolome and stool microbiota will be conducted with the collaboration of Dr. Ruth Ann Luna and Dr. Jim Versalovic at Alkek Center for Metagenomics and Microbiome Research, Department of Molecular Virology \& Microbiology of Baylor College of Medicine.

Official title: Road to Discovery for Combination Probiotic BB-12 With LGG (Different Doses) in Treating Autism Spectrum Disorder Disorders

Key Details

Gender

All

Age Range

4 Years - 16 Years

Study Type

INTERVENTIONAL

Enrollment

70

Start Date

2016-05

Completion Date

2025-12

Last Updated

2024-05-08

Healthy Volunteers

Yes

Interventions

DRUG

BB-12 with LGG (Higher Dose)

BB-12 with LGG - Higher Dose (10 billion CFUs)

DRUG

Placebo

Maltodextrin

DRUG

BB-12 with LGG (Lower Dose)

BB-12 with LGG - Lower Dose (1 billion CFUs)

Locations (1)

UTHealth

Houston, Texas, United States